Cancer Vaccines Market - Global Forecast To 2032
商品番号 : SMB-70848
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年12月 |
| ページ数 | 263 |
| 図表数 | 342 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global cancer vaccines market is projected to surpass USD 20.47 billion in 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%.
世界のがんワクチン市場は、2024年の106億1,000万米ドルから2032年には204億7,000万米ドルを超え、8.6%という大幅なCAGRで成長すると予測されています。
The market is witnessing robust growth, fueled by rising cancer prevalence and advancements in immunotherapy technologies like mRNA platforms. Preventive vaccines such as Gardasil (HPV) and therapeutic candidates like neoantigen vaccines are driving innovation in the market. Strong R&D investments, especially in North America and Europe, combined with increasing demand for personalized therapies, are further accelerating adoption.
“The preventive cancer vaccines segment accounted for the highest share in 2023.”
On the basis of type, the cancer vaccines market is further segmented into preventive and therapeutic vaccines (Neoantigen cancer vaccines and other cancer vaccines). The preventive cancer vaccines segment is anticipated to lead the cancer vaccines market, driven by increasing awareness of disease prevention, government immunization programs, and technological advancements in vaccine development. Emerging technologies, such as mRNA platforms, are further likely to enhance vaccine efficacy and accessibility is likely to boost the segmental growth.
“By route of administration, intramuscular segment accounted for the largest share in the cancer vaccines market.”
The route of administration segment of the cancer vaccines market is segmented into intravenous, intramuscular, and other route of administration. Intramuscular (IM) route of administration is expected to lead the cancer vaccines market owing to the established practice, high efficacy of the administration of the vaccine, and creation of an effective immune response. IM administration guarantees a high efficiency of vaccine absorption and compatibility with any kind of formulation, therefore it is the most appropriate for preventive and treatment cancer vaccines. Its ease of use in clinical and outpatient settings, along with minimal training requirements for healthcare providers, enhances accessibility and scalability for mass immunization programs. All of these parameters therefore position the IM route as the dominant and feasible option in the cancer vaccine field.
“North America: the largest share of the cancer vaccines market”
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America dominated the cancer vaccines market in 2023 and is estimated to continue dominance during the forecast period. Advanced healthcare infrastructure, high levels of investment in biotechnology, and strong presence of leading pharmaceutical companies driving innovation in the field. are some of the prominent factors accelerating market growth.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cancer vaccines market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 65% and Demand Side 35%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others are some of the major players operating in the cancer vaccines market.
Research Coverage:
This research report categorizes the cancer vacciness market type (preventive and therapeutic [neoantigen cancer vaccines & other cancer vaccines]), technology (cell-based vaccines, recombinant, others), route of administration (intramuscular, intravenous, other routes of administration), indication (cervical cancer, prostrate cancer, other indications), end user (hospitals, others) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cancer vacciness market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cancer vaccines market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cancer vaccines and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (Increasing Awareness and Preventive Healthcare Measures, Rising Cancer Incidence Globally, Increased investments into R&D of Neoantigen cancer vaccines and Technological Advancements in Immunotherapy), restraints (Lengthy Clinical Trial Processes and Vaccine Hesitancy & Limited Adoption and High Development and Manufacturing Costs), opportunities (Collaborations & Strategic Partnerships and Incorporation of Artificial Intelligence (AI) & Big Data) and Challenges (Personalized Medicine & Heterogeneity of Cancer Types and Competition from Alternative Therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies in cancer vaccines manufacturing, research and development activities, and new product launches in the cancer vaccines market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cancer vaccines market
- Competitive Assessment: Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others in the market.
Table of Contents
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION 27
1.3.2 INCLUSIONS & EXCLUSIONS 28
1.3.3 YEARS CONSIDERED 28
1.3.4 CURRENCY CONSIDERED 28
1.4 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 31
2.1.2 PRIMARY DATA 32
2.2 MARKET ESTIMATION METHODOLOGY 33
2.2.1 MARKET ESTIMATION 33
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 35
2.2.3 TOP-DOWN APPROACH 36
2.3 MARKET GROWTH RATE PROJECTION 37
2.4 DATA TRIANGULATION 39
2.5 RESEARCH ASSUMPTIONS 39
2.6 RESEARCH LIMITATIONS 40
2.7 RISK ANALYSIS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHTS 47
4.1 CANCER VACCINES MARKET OVERVIEW 47
4.2 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY AND COUNTRY (2023) 48
4.3 CANCER VACCINES MARKET SHARE, BY TYPE, 2024 VS. 2032 48
4.4 CANCER VACCINES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 49
5 MARKET OVERVIEW 50
5.1 INTRODUCTION 50
5.2 MARKET DYNAMICS 50
5.2.1 DRIVERS 51
5.2.1.1 Increased investments in neoantigen cancer vaccine R&D 51
5.2.1.2 Technological advancements in immunotherapy 51
5.2.1.3 Increasing awareness and preventive healthcare measures 52
5.2.1.4 Rising cancer incidence globally 53
5.2.2 RESTRAINTS 53
5.2.2.1 High development and manufacturing costs 53
5.2.2.2 Lengthy clinical trial processes & vaccine hesitancy and limited adoption 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Collaborations and strategic partnerships 55
5.2.3.2 Incorporation of AI and big data 56
5.2.4 CHALLENGES 57
5.2.4.1 Personalized medicine and heterogeneity of cancer types 57
5.2.4.2 Competition from alternative therapies 57
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 58
5.4 VALUE CHAIN ANALYSIS 59
5.5 ECOSYSTEM ANALYSIS 60
5.5.1 RAW MATERIAL PROVIDERS 61
5.5.2 PRODUCT PROVIDERS 62
5.5.3 END USERS 63
5.5.4 REGULATORY LANDSCAPE 63
5.6 TECHNOLOGY ANALYSIS 64
5.6.1 KEY TECHNOLOGIES 65
5.6.1.1 mRNA-based vaccines 65
5.6.1.2 Dendritic cell vaccines 65
5.6.1.3 Recombinant vector-based vaccines 66
5.6.2 COMPLEMENTARY TECHNOLOGIES 66
5.6.2.1 Artificial Intelligence (AI) and Machine Learning (ML) 66
5.6.2.2 Adjuvants for immuno-stimulation 66
5.6.3 ADJACENT TECHNOLOGIES 67
5.6.3.1 CAR T-cell therapy 67
5.6.3.2 CRISPR-based gene editing 67
5.7 PATENT ANALYSIS 68
5.7.1 METHODOLOGY 68
5.7.2 NUMBER OF PATENTS FILED 68
5.7.3 INNOVATIONS AND PATENT APPLICATIONS 68
5.8 PRICING ANALYSIS 71
5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, 2021–2023 71
5.8.2 AVERAGE SELLING PRICE, BY REGION, 2023 72
5.9 KEY CONFERENCES & EVENTS, 2024–2O25 73
5.10 REGULATORY LANDSCAPE 74
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
5.10.2 REGULATORY FRAMEWORK 77
5.10.2.1 North America 77
5.10.2.2 Europe 77
5.10.2.3 Asia Pacific 77
5.11 INVESTMENT & FUNDING SCENARIO 78
5.12 PORTER’S FIVE FORCES ANALYSIS 80
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 81
5.12.2 BARGAINING POWER OF SUPPLIERS 81
5.12.3 BARGAINING POWER OF BUYERS 81
5.12.4 THREAT OF SUBSTITUTES 81
5.12.5 THREAT OF NEW ENTRANTS 81
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 82
5.13.1 KEY STAKEHOLDERS 82
5.13.2 KEY BUYING CRITERIA 83
5.14 TRADE ANALYSIS 85
5.14.1 IMPORT DATA FOR HS CODE 300241 85
5.14.2 EXPORT DATA FOR HS CODE 300241 86
5.15 IMPACT OF AI/GEN AI ON CANCER VACCINES MARKET 88
5.16 PIPELINE ANALYSIS 90
6 CANCER VACCINES MARKET, BY TYPE 91
6.1 INTRODUCTION 92
6.2 PREVENTIVE VACCINES 92
6.2.1 NATIONAL IMMUNIZATION PROGRAMS & BIOTECHNOLOGY INNOVATIONS TO DRIVE MARKET GROWTH 92
6.3 THERAPEUTIC VACCINES 95
6.3.1 NEOANTIGEN CANCER VACCINES 99
6.3.1.1 Personalized nature of neoantigen cancer vaccines to propel market growth 99
6.3.2 OTHER THERAPEUTIC VACCINES 102
7 CANCER VACCINES MARKET, BY TECHNOLOGY 106
7.1 INTRODUCTION 107
7.2 CELL-BASED VACCINES 107
7.2.1 ADVANCEMENTS IN MANUFACTURING PROCESSES TO DRIVE MARKET GROWTH 107
7.3 RECOMBINANT VACCINES 110
7.3.1 GLOBAL VACCINATION INITIATIVES TO PROPEL MARKET 110
7.4 OTHER VACCINE TECHNOLOGIES 113
8 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION 117
8.1 INTRODUCTION 118
8.2 INTRAMUSCULAR ROUTE 118
8.2.1 TECHNOLOGICAL ADVANCEMENTS IN VACCINE DELIVERY TO SUPPORT MARKET GROWTH 118
8.3 OTHER ROUTES OF ADMINISTRATION 121
9 CANCER VACCINES MARKET, BY INDICATION 125
9.1 INTRODUCTION 126
9.2 CERVICAL & RELATED CANCERS 126
9.2.1 RISING CERVICAL CANCER PREVALENCE TO SUPPORT MARKET GROWTH 126
9.3 OTHER INDICATIONS 129
10 CANCER VACCINES MARKET, BY END USER 133
10.1 INTRODUCTION 134
10.2 HOSPITALS 134
10.2.1 RISING CANCER PREVALENCE TO SUPPORT MARKET GROWTH 134
10.3 SPECIALTY CLINICS & CENTERS 137
10.3.1 INCREASING AWARENESS AND ACCESS TO PROPEL MARKET 137
11 CANCER VACCINES MARKET, BY REGION 141
11.1 INTRODUCTION 142
11.2 ASIA PACIFIC 142
11.2.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 143
11.2.2 CHINA 147
11.2.2.1 Government support & strategic initiatives by key players to strengthen biotechnology sector in China 147
11.2.3 JAPAN 150
11.2.3.1 Government initiatives for vaccines to boost market 150
11.2.4 INDIA 152
11.2.4.1 Growth of biotechnology sector and development of new vaccines to drive market 152
11.2.5 SOUTH KOREA 155
11.2.5.1 Commitment to cancer immunotherapy to expand cancer vaccine sector 155
11.2.6 REST OF ASIA PACIFIC 157
11.3 NORTH AMERICA 160
11.3.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160
11.3.2 US 164
11.3.2.1 US to dominate North American market during forecast period 164
11.3.3 CANADA 167
11.3.3.1 Increasing government funding for vaccine research to drive market growth in Canada 167
11.4 EUROPE 169
11.4.1 MACROECONOMIC OUTLOOK FOR EUROPE 169
11.4.2 GERMANY 173
11.4.2.1 Increasing investments by key players and growing funding from government organizations to drive market 173
11.4.3 UK 175
11.4.3.1 Rising investments in vaccine development to boost market growth 175
11.4.4 FRANCE 178
11.4.4.1 Support for biotechnology and research to drive market growth 178
11.4.5 ITALY 181
11.4.5.1 Government initiatives for vaccine development to boost market growth 181
11.4.6 SPAIN 183
11.4.6.1 Increasing investments in vaccine development by government and private organizations to support market growth 183
11.4.7 REST OF EUROPE 186
11.5 LATIN AMERICA 188
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 188
11.5.2 BRAZIL 191
11.5.2.1 Proactive healthcare policies to support market growth 191
11.5.3 MEXICO 194
11.5.3.1 Government commitment to immunization programs to fuel growth 194
11.5.4 REST OF LATIN AMERICA 196
11.6 MIDDLE EAST 198
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 198
11.6.2 GCC COUNTRIES 202
11.6.3 REST OF MIDDLE EAST 204
11.7 AFRICA 206
11.7.1 INCREASING INVESTMENTS IN CANCER VACCINE IMMUNIZATION PROGRAMS TO SUPPORT MARKET GROWTH 206
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 207
12 COMPETITIVE LANDSCAPE 210
12.1 OVERVIEW 210
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023 210
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CANCER VACCINES MARKET 210
12.3 REVENUE ANALYSIS, 2019–2023 212
12.4 MARKET RANKING, 2023 AND 2032 212
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 214
12.5.1 STARS 214
12.5.2 EMERGING LEADERS 214
12.5.3 PERVASIVE PLAYERS 215
12.5.4 PARTICIPANTS 215
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 216
12.5.5.1 Company footprint 216
12.5.5.2 Region footprint 216
12.5.5.3 Type footprint 217
12.5.5.4 Technology footprint 217
12.5.5.5 Route of administration footprint 218
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 218
12.6.1 PROGRESSIVE COMPANIES 218
12.6.2 RESPONSIVE COMPANIES 218
12.6.3 DYNAMIC COMPANIES 218
12.6.4 STARTING BLOCKS 219
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 220
12.7 COMPANY VALUATION & FINANCIAL METRICS 221
12.7.1 FINANCIAL METRICS 221
12.7.2 COMPANY VALUATION 221
12.8 BRAND/PRODUCT COMPARISON 222
12.9 COMPETITIVE SCENARIO 222
12.9.1 PRODUCT LAUNCHES & APPROVALS 222
12.9.2 DEALS 223
12.9.3 EXPANSIONS 224
13 COMPANY PROFILES 225
13.1 KEY PLAYERS 225
13.1.1 MERCK & CO., INC. 225
13.1.1.1 Business overview 225
13.1.1.2 Products offered 226
13.1.1.3 Recent developments 227
13.1.1.3.1 Deals 227
13.1.1.3.2 Expansions 227
13.1.1.4 MnM view 228
13.1.1.4.1 Key strengths 228
13.1.1.4.2 Strategic choices 228
13.1.1.4.3 Weaknesses & competitive threats 228
13.1.2 GSK PLC. 229
13.1.2.1 Business overview 229
13.1.2.2 Products offered 230
13.1.2.3 Recent developments 231
13.1.2.3.1 Product approvals 231
13.1.2.4 MnM view 231
13.1.2.4.1 Key strengths 231
13.1.2.4.2 Strategic choices 231
13.1.2.4.3 Weaknesses & competitive threats 231
13.1.3 DENDREON PHARMACEUTICALS LLC. (SANPOWER GROUP) 232
13.1.3.1 Business overview 232
13.1.3.2 Products offered 232
13.1.3.3 MnM view 233
13.1.3.3.1 Key strengths 233
13.1.3.3.2 Strategic choices 233
13.1.3.3.3 Weaknesses & competitive threats 233
13.1.4 JW CREAGENE (JW SHINYAK) 234
13.1.4.1 Business overview 234
13.1.4.2 Products offered 234
13.1.5 SERUM INSTITUTE OF INDIA PVT. LTD. 235
13.1.5.1 Business overview 235
13.1.5.2 Products offered 235
13.1.5.3 Recent developments 236
13.1.5.3.1 Product launches 236
13.1.5.3.2 Deals 236
13.1.6 VERITY PHARMACEUTICALS, INC. 237
13.1.6.1 Business overview 237
13.1.6.2 Products offered 237
13.1.6.3 Recent developments 238
13.1.6.3.1 Product approvals 238
13.1.7 WANTAI BIOPHARM 239
13.1.7.1 Business overview 239
13.1.7.2 Products offered 239
13.1.8 SHANGHAI ZERUN BIOTECH CO., LTD. (WALVAX BIOTECHNOLOGY CO., LTD.) 240
13.1.8.1 Business overview 240
13.1.8.2 Products offered 240
13.1.8.3 Recent developments 241
13.1.8.3.1 Product approvals 241
13.1.9 VACCINOGEN 242
13.1.9.1 Business overview 242
13.1.9.2 Products offered 242
13.2 OTHER PLAYERS (COMPANIES WITH PRODUCTS UNDER CLINICAL STUDIES) 243
13.2.1 BIONTECH 243
13.2.1.1 BioNTech: Products under clinical studies 243
13.2.2 GRITSTONE BIO 244
13.2.2.1 Gritstone Bio: Products under clinical studies 244
13.2.3 OSE-IMMUNO 245
13.2.3.1 OSE-Immuno: Products under clinical studies 245
13.2.4 OBI PHARMA 246
13.2.4.1 OBI Pharma: Products under clinical studies 246
13.2.5 SHANGHAI BOVAX BIOTECHNOLOGY CO., LTD. 247
13.2.5.1 Shanghai Bovax Biotechnology: Products under clinical studies 247
13.2.6 MODERNA INC. 248
13.2.6.1 Moderna: Products under clinical studies 248
13.2.7 BEIJING SINOCELL BIOTECHNOLOGY GROUP CO., LTD. 249
13.2.7.1 Beijing Sinocell Biotechnology Group: Products under clinical studies 249
13.2.8 GREENWICH LIFESCIENCES, INC. 250
13.2.8.1 Greenwich LifeSciences: Products under clinical studies 250
13.2.9 ASTON SCI. INC. 251
13.2.9.1 Aston Sci.: Products under clinical studies 251
13.2.10 TRANSGENE 252
13.2.10.1 Transgene: Products under clinical studies 252
13.2.11 SELLAS LIFE SCIENCES GROUP INC. 253
13.2.11.1 Sellas Life Sciences Group: Products under clinical studies 253
14 APPENDIX 254
14.1 DISCUSSION GUIDE 254
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 259
14.3 CUSTOMIZATION OPTIONS 261
14.4 RELATED REPORTS 261
14.5 AUTHOR DETAILS 262
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 38
TABLE 2 CANCER VACCINES MARKET: RISK ASSESSMENT ANALYSIS 41
TABLE 3 KEY RAW MATERIAL PROVIDERS IN CANCER VACCINES MARKET 62
TABLE 4 KEY PRODUCT PROVIDERS IN CANCER VACCINES MARKET 62
TABLE 5 KEY END USERS IN CANCER VACCINES MARKET 63
TABLE 6 KEY REGULATORY BODIES IN CANCER VACCINES MARKET 64
TABLE 7 NUMBER OF PATENTS FILED IN CANCER VACCINES MARKET, BY DOCUMENT TYPE, 2014–2024 68
TABLE 8 LIST OF PATENTS IN CANCER VACCINES MARKET, 2023–2024 69
TABLE 9 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE, 2021–2023 71
TABLE 10 AVERAGE SELLING PRICE OF CANCER VACCINES, BY REGION, 2023 72
TABLE 11 KEY CONFERENCES & EVENTS, JUNE 2024–DECEMBER 2025 73
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 13 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 14 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 15 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 16 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76
TABLE 17 CANCER VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 80
TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 82
TABLE 19 KEY BUYING CRITERIA FOR TOP THREE END USERS 83
TABLE 20 IMPORT VALUE FOR HS CODE 300241, 2019–2023 (USD THOUSAND) 85
TABLE 21 IMPORT VOLUME FOR HS CODE 300241, 2019–2023 (TONS) 86
TABLE 22 EXPORT VALUE FOR HS CODE 300241, 2019–2023 (USD THOUSAND) 86
TABLE 23 EXPORT VOLUME FOR HS CODE 300241, 2019–2023 (TONS) 87
TABLE 24 CANCER VACCINES MARKET: PRODUCTS IN PIPELINE AND LAUNCH DATES 90
TABLE 25 CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 92
TABLE 26 PREVENTIVE CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION) 93
TABLE 27 NORTH AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 93
TABLE 28 EUROPE: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 94
TABLE 29 ASIA PACIFIC: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 94
TABLE 30 LATIN AMERICA: PREVENTIVE CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 95
TABLE 31 MIDDLE EAST: PREVENTIVE CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 95
TABLE 32 THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 96
TABLE 33 THERAPEUTIC CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 96
TABLE 34 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 97
TABLE 35 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 97
TABLE 36 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 98
TABLE 37 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 98
TABLE 38 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 98
TABLE 39 NEOANTIGEN CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 100
TABLE 40 NORTH AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 100
TABLE 41 EUROPE: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 101
TABLE 42 ASIA PACIFIC: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 101
TABLE 43 LATIN AMERICA: NEOANTIGEN CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 102
TABLE 44 MIDDLE EAST: NEOANTIGEN CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 102
TABLE 45 OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 103
TABLE 46 NORTH AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 103
TABLE 47 EUROPE: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 104
TABLE 48 ASIA PACIFIC: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 104
TABLE 49 LATIN AMERICA: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 105
TABLE 50 MIDDLE EAST: OTHER THERAPEUTIC CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION) 105
TABLE 51 CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 107
TABLE 52 CELL-BASED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION) 108
TABLE 53 NORTH AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 108
TABLE 54 EUROPE: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 109
TABLE 55 ASIA PACIFIC: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 109
TABLE 56 LATIN AMERICA: CELL-BASED CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 110
TABLE 57 MIDDLE EAST: CELL-BASED CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 110
TABLE 58 RECOMBINANT CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 111
TABLE 59 NORTH AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 111
TABLE 60 EUROPE: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 112
TABLE 61 ASIA PACIFIC: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 112
TABLE 62 LATIN AMERICA: RECOMBINANT CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 113
TABLE 63 MIDDLE EAST: RECOMBINANT CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 113
TABLE 64 OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION,
2022–2032 (USD MILLION) 114
TABLE 65 NORTH AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 114
TABLE 66 EUROPE: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 115
TABLE 67 ASIA PACIFIC: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 115
TABLE 68 LATIN AMERICA: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 116
TABLE 69 MIDDLE EAST: OTHER CANCER VACCINE TECHNOLOGIES MARKET, BY REGION, 2022–2032 (USD MILLION) 116
TABLE 70 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 118
TABLE 71 CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY REGION,
2022–2032 (USD MILLION) 119
TABLE 72 NORTH AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE,
BY COUNTRY, 2022–2032 (USD MILLION) 119
TABLE 73 EUROPE: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE, BY COUNTRY, 2022–2032 (USD MILLION) 120
TABLE 74 ASIA PACIFIC: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE,
BY COUNTRY, 2022–2032 (USD MILLION) 120
TABLE 75 LATIN AMERICA: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE,
BY COUNTRY, 2022–2032 (USD MILLION) 121
TABLE 76 MIDDLE EAST: CANCER VACCINES MARKET FOR INTRAMUSCULAR ROUTE,
BY REGION, 2022–2032 (USD MILLION) 121
TABLE 77 CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2022–2032 (USD MILLION) 122
TABLE 78 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 123
TABLE 79 EUROPE: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 123
TABLE 80 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 124
TABLE 81 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2032 (USD MILLION) 124
TABLE 82 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2032 (USD MILLION) 124
TABLE 83 CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 126
TABLE 84 CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 127
TABLE 85 NORTH AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET,
BY COUNTRY, 2022–2032 (USD MILLION) 127
TABLE 86 EUROPE: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY,
2022–2032(USD MILLION) 128
TABLE 87 ASIA PACIFIC: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 128
TABLE 88 LATIN AMERICA: CERVICAL & RELATED CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 129
TABLE 89 MIDDLE EAST: CERVICAL & RELATED CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION) 129
TABLE 90 CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION,
2022–2032 (USD MILLION) 130
TABLE 91 NORTH AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD MILLION) 130
TABLE 92 EUROPE: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032(USD MILLION) 131
TABLE 93 ASIA PACIFIC: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2032 (USD MILLION) 131
TABLE 94 LATIN AMERICA: CANCER VACCINES MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2022–2032 (USD MILLION) 132
TABLE 95 MIDDLE EAST: CANCER VACCINES MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2032 (USD MILLION) 132
TABLE 96 CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 134
TABLE 97 CANCER VACCINES MARKET FOR HOSPITALS, BY REGION,
2022–2032 (USD MILLION) 135
TABLE 98 NORTH AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 135
TABLE 99 EUROPE: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 136
TABLE 100 ASIA PACIFIC: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY,
2022–2032 (USD MILLION) 136
TABLE 101 LATIN AMERICA: CANCER VACCINES MARKET FOR HOSPITALS, BY COUNTRY, 2022–2032 (USD MILLION) 137
TABLE 102 MIDDLE EAST: CANCER VACCINES MARKET FOR HOSPITALS, BY REGION,
2022–2032 (USD MILLION) 137
TABLE 103 CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022–2032 (USD MILLION) 138
TABLE 104 NORTH AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 138
TABLE 105 EUROPE: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS,
BY COUNTRY, 2022–2032 (USD MILLION) 139
TABLE 106 ASIA PACIFIC: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 139
TABLE 107 LATIN AMERICA: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY COUNTRY, 2022–2032 (USD MILLION) 140
TABLE 108 MIDDLE EAST: CANCER VACCINES MARKET FOR SPECIALTY CLINICS & CENTERS, BY REGION, 2022–2032 (USD MILLION) 140
TABLE 109 CANCER VACCINES MARKET, BY REGION, 2022–2032 (USD MILLION) 142
TABLE 110 ASIA PACIFIC: KEY MACROINDICATORS 143
TABLE 111 ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 145
TABLE 112 ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 145
TABLE 113 ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 145
TABLE 114 ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 146
TABLE 115 ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 146
TABLE 116 ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 146
TABLE 117 ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 147
TABLE 118 CHINA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 148
TABLE 119 CHINA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 148
TABLE 120 CHINA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 148
TABLE 121 CHINA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 149
TABLE 122 CHINA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 149
TABLE 123 CHINA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 149
TABLE 124 JAPAN: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 150
TABLE 125 JAPAN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 150
TABLE 126 JAPAN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 151
TABLE 127 JAPAN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 151
TABLE 128 JAPAN: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 151
TABLE 129 JAPAN: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 152
TABLE 130 INDIA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 153
TABLE 131 INDIA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 153
TABLE 132 INDIA: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 153
TABLE 133 INDIA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 154
TABLE 134 INDIA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 154
TABLE 135 INDIA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 154
TABLE 136 SOUTH KOREA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 155
TABLE 137 SOUTH KOREA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 155
TABLE 138 SOUTH KOREA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 156
TABLE 139 SOUTH KOREA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 156
TABLE 140 SOUTH KOREA: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 156
TABLE 141 SOUTH KOREA: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 157
TABLE 142 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 158
TABLE 143 REST OF ASIA PACIFIC: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 158
TABLE 144 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 158
TABLE 145 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 159
TABLE 146 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 159
TABLE 147 REST OF ASIA PACIFIC: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 159
TABLE 148 NORTH AMERICA: KEY MACROINDICATORS 161
TABLE 149 NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 162
TABLE 150 NORTH AMERICA: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 162
TABLE 151 NORTH AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 162
TABLE 152 NORTH AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 163
TABLE 153 NORTH AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 163
TABLE 154 NORTH AMERICA: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 163
TABLE 155 NORTH AMERICA: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 164
TABLE 156 US: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 165
TABLE 157 US: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 165
TABLE 158 US: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 165
TABLE 159 US: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 166
TABLE 160 US: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 166
TABLE 161 US: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 166
TABLE 162 CANADA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 167
TABLE 163 CANADA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 168
TABLE 164 CANADA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 168
TABLE 165 CANADA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 168
TABLE 166 CANADA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 169
TABLE 167 CANADA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 169
TABLE 168 EUROPE: KEY MACROINDICATORS 170
TABLE 169 EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022–2032 (USD MILLION) 170
TABLE 170 EUROPE: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 171
TABLE 171 EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 171
TABLE 172 EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 171
TABLE 173 EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 172
TABLE 174 EUROPE: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 172
TABLE 175 EUROPE: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 172
TABLE 176 GERMANY: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 173
TABLE 177 GERMANY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 174
TABLE 178 GERMANY: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 174
TABLE 179 GERMANY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 174
TABLE 180 GERMANY: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 175
TABLE 181 GERMANY: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 175
TABLE 182 UK: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 176
TABLE 183 UK: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 176
TABLE 184 UK: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 177
TABLE 185 UK: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 177
TABLE 186 UK: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 177
TABLE 187 UK: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 178
TABLE 188 FRANCE: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 179
TABLE 189 FRANCE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 179
TABLE 190 FRANCE: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 179
TABLE 191 FRANCE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 180
TABLE 192 FRANCE: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 180
TABLE 193 FRANCE: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 180
TABLE 194 ITALY: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 181
TABLE 195 ITALY: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 182
TABLE 196 ITALY: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 182
TABLE 197 ITALY: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 182
TABLE 198 ITALY: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 183
TABLE 199 ITALY: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 183
TABLE 200 SPAIN: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 184
TABLE 201 SPAIN: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 184
TABLE 202 SPAIN: CANCER VACCINES MARKET, BY TECHNOLOGY, 2022–2032 (USD MILLION) 184
TABLE 203 SPAIN: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 185
TABLE 204 SPAIN: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 185
TABLE 205 SPAIN: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 185
TABLE 206 REST OF EUROPE: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 186
TABLE 207 REST OF EUROPE: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 186
TABLE 208 REST OF EUROPE: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 187
TABLE 209 REST OF EUROPE: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 187
TABLE 210 REST OF EUROPE: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 187
TABLE 211 REST OF EUROPE: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 188
TABLE 212 LATIN AMERICA: KEY MACROINDICATORS 189
TABLE 213 LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY,
2022–2032 (USD MILLION) 189
TABLE 214 LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 189
TABLE 215 LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 190
TABLE 216 LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 190
TABLE 217 LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 190
TABLE 218 LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 191
TABLE 219 LATIN AMERICA: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 191
TABLE 220 BRAZIL: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 192
TABLE 221 BRAZIL: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 192
TABLE 222 BRAZIL: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 192
TABLE 223 BRAZIL: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 193
TABLE 224 BRAZIL: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 193
TABLE 225 BRAZIL: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 193
TABLE 226 MEXICO: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 194
TABLE 227 MEXICO: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 194
TABLE 228 MEXICO: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 195
TABLE 229 MEXICO: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 195
TABLE 230 MEXICO: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 195
TABLE 231 MEXICO: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 196
TABLE 232 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 196
TABLE 233 REST OF LATIN AMERICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 197
TABLE 234 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 197
TABLE 235 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 197
TABLE 236 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 198
TABLE 237 REST OF LATIN AMERICA: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 198
TABLE 238 MIDDLE EAST: KEY MACROINDICATORS 199
TABLE 239 MIDDLE EAST: CANCER VACCINES MARKET, BY REGION,
2022–2032 (USD MILLION) 199
TABLE 240 MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 200
TABLE 241 MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 200
TABLE 242 MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 200
TABLE 243 MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 201
TABLE 244 MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 201
TABLE 245 MIDDLE EAST: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 201
TABLE 246 GCC COUNTRIES: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 202
TABLE 247 GCC COUNTRIES: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 202
TABLE 248 GCC COUNTRIES: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 203
TABLE 249 GCC COUNTRIES: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 203
TABLE 250 GCC COUNTRIES: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 203
TABLE 251 GCC COUNTRIES: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 204
TABLE 252 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 204
TABLE 253 REST OF MIDDLE EAST: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 205
TABLE 254 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 205
TABLE 255 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2022–2032 (USD MILLION) 205
TABLE 256 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY INDICATION,
2022–2032 (USD MILLION) 206
TABLE 257 REST OF MIDDLE EAST: CANCER VACCINES MARKET, BY END USER,
2022–2032 (USD MILLION) 206
TABLE 258 AFRICA: KEY MACROINDICATORS 207
TABLE 259 AFRICA: CANCER VACCINES MARKET, BY TYPE, 2022–2032 (USD MILLION) 208
TABLE 260 AFRICA: THERAPEUTIC CANCER VACCINES MARKET, BY TYPE,
2022–2032 (USD MILLION) 208
TABLE 261 AFRICA: CANCER VACCINES MARKET, BY TECHNOLOGY,
2022–2032 (USD MILLION) 208
TABLE 262 AFRICA: CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2022–2032 (USD MILLION) 209
TABLE 263 AFRICA: CANCER VACCINES MARKET, BY INDICATION, 2022–2032 (USD MILLION) 209
TABLE 264 AFRICA: CANCER VACCINES MARKET, BY END USER, 2022–2032 (USD MILLION) 209
TABLE 265 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2021-2024 210
TABLE 266 CANCER VACCINES MARKET SHARE RANKING (2023) 213
TABLE 267 CANCER VACCINES MARKET SHARE RANKING (2032) 213
TABLE 268 CANCER VACCINES MARKET: REGION FOOTPRINT 216
TABLE 269 CANCER VACCINES MARKET: TYPE FOOTPRINT 217
TABLE 270 CANCER VACCINES MARKET: TECHNOLOGY FOOTPRINT 217
TABLE 271 CANCER VACCINES MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 218
TABLE 272 CANCER VACCINES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 220
TABLE 273 CANCER VACCINES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 220
TABLE 274 CANCER VACCINES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–NOVEMBER 2024 222
TABLE 275 CANCER VACCINES MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 223
TABLE 276 CANCER VACCINES MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 224
TABLE 277 MERCK: COMPANY OVERVIEW 225
TABLE 278 MERCK: PRODUCTS OFFERED 226
TABLE 279 MERCK: DEALS, JANUARY 2021–NOVEMBER 2024 227
TABLE 280 MERCK: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 227
TABLE 281 GSK: COMPANY OVERVIEW 229
TABLE 282 GSK: PRODUCTS OFFERED 230
TABLE 283 GSK: PRODUCT APPROVALS, JANUARY 2021–NOVEMBER 2024 231
TABLE 284 DENDREON PHARMACEUTICALS: COMPANY OVERVIEW 232
TABLE 285 DENDREON PHARMACEUTICALS: PRODUCTS OFFERED 232
TABLE 286 JW CREAGENE: COMPANY OVERVIEW 234
TABLE 287 JW CREAGENE: PRODUCTS OFFERED 234
TABLE 288 SERUM INSTITUTE OF INDIA: COMPANY OVERVIEW 235
TABLE 289 SERUM INSTITUTE OF INDIA: PRODUCTS OFFERED 235
TABLE 290 SERUM INSTITUTE OF INDIA: PRODUCT LAUNCHES,
JANUARY 2021–NOVEMBER 2024 236
TABLE 291 SERUM INSTITUTE OF INDIA: DEALS, JANUARY 2021–NOVEMBER 2024 236
TABLE 292 VERITY PHARMACEUTICALS: COMPANY OVERVIEW 237
TABLE 293 VERITY PHARMACEUTICALS: PRODUCTS OFFERED 237
TABLE 294 VERITY PHARMACEUTICALS: PRODUCT APPROVALS,
JANUARY 2021–NOVEMBER 2024 238
TABLE 295 WANTAI BIOPHARM: COMPANY OVERVIEW 239
TABLE 296 WANTAI BIOPHARM: PRODUCTS OFFERED 239
TABLE 297 SHANGHAI ZERUN BIOTECHNOLOGY: COMPANY OVERVIEW 240
TABLE 298 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCTS OFFERED 240
TABLE 299 SHANGHAI ZERUN BIOTECHNOLOGY: PRODUCT APPROVALS,
JANUARY 2021–NOVEMBER 2024 241
TABLE 300 VACCINOGEN: COMPANY OVERVIEW 242
TABLE 301 VACCINOGEN: PRODUCTS OFFERED 242
LIST OF FIGURES
FIGURE 1 CANCER VACCINES MARKET SEGMENTATION 27
FIGURE 2 RESEARCH DESIGN 30
FIGURE 3 BREAKDOWN OF PRIMARIES: CANCER VACCINES MARKET 32
FIGURE 4 CANCER VACCINES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023 33
FIGURE 5 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (PRODUCTS), 2023 34
FIGURE 6 ILLUSTRATIVE EXAMPLE OF MERCK & CO., INC.: REVENUE SHARE ANALYSIS (2023) 34
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 35
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 36
FIGURE 9 CANCER VACCINES MARKET: CAGR PROJECTIONS 37
FIGURE 10 DATA TRIANGULATION METHODOLOGY 39
FIGURE 11 CANCER VACCINES MARKET, BY TYPE, 2024 VS. 2032 (USD MILLION) 42
FIGURE 12 CANCER VACCINES MARKET, BY TECHNOLOGY, 2024 VS. 2032 (USD MILLION) 43
FIGURE 13 CANCER VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
2024 VS. 2032 (USD MILLION) 43
FIGURE 14 CANCER VACCINES MARKET, BY INDICATION, 2024 VS. 2032 (USD MILLION) 44
FIGURE 15 CANCER VACCINES MARKET, BY END USER, 2024 VS. 2032 (USD MILLION) 45
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CANCER VACCINES MARKET (2024–2032) 45
FIGURE 17 ADVANCEMENTS IN CANCER VACCINES AND RISING DEMAND FOR NEOANTIGEN CANCER VACCINES TO DRIVE MARKET 47
FIGURE 18 RECOMBINANT VACCINES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 48
FIGURE 19 PREVENTIVE VACCINES TO DOMINATE MARKET DURING FORECAST PERIOD 48
FIGURE 20 US TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49
FIGURE 21 CANCER VACCINES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 50
FIGURE 22 TRENDS/DISRUPTIONS INFLUENCING CUSTOMERS’ BUSINESS 58
FIGURE 23 CANCER VACCINES MARKET: VALUE CHAIN ANALYSIS 59
FIGURE 24 CANCER VACCINES MARKET: ECOSYSTEM ANALYSIS 61
FIGURE 25 CANCER VACCINES MARKET: PATENT ANALYSIS 69
FIGURE 26 CANCER VACCINES MARKET: FUNDING SCENARIO 79
FIGURE 27 CANCER VACCINES MARKET: PORTER’S FIVE FORCES ANALYSIS 80
FIGURE 28 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS 82
FIGURE 29 KEY BUYING CRITERIA FOR TOP END USERS 83
FIGURE 30 CANCER VACCINES MARKET: IMPACT OF AI 89
FIGURE 31 ASIA PACIFIC: CANCER VACCINES MARKET SNAPSHOT 144
FIGURE 32 NORTH AMERICA: CANCER VACCINES MARKET SNAPSHOT 161
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN CANCER VACCINES MARKET,
2019–2023 212
FIGURE 34 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 215
FIGURE 35 CANCER VACCINES MARKET: COMPANY FOOTPRINT 216
FIGURE 36 CANCER VACCINES MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2023 219
FIGURE 37 EV/EBITDA OF KEY VENDORS 221
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 221
FIGURE 39 CANCER VACCINES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 222
FIGURE 40 MERCK: COMPANY SNAPSHOT (2023) 226
FIGURE 41 GSK: COMPANY SNAPSHOT (2023) 230
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11